BR112016012237B1 - Métodos úteis na síntese de análogos de halicondrina b - Google Patents

Métodos úteis na síntese de análogos de halicondrina b Download PDF

Info

Publication number
BR112016012237B1
BR112016012237B1 BR112016012237-2A BR112016012237A BR112016012237B1 BR 112016012237 B1 BR112016012237 B1 BR 112016012237B1 BR 112016012237 A BR112016012237 A BR 112016012237A BR 112016012237 B1 BR112016012237 B1 BR 112016012237B1
Authority
BR
Brazil
Prior art keywords
eribulin
salt
alkyl
pharmaceutically acceptable
produce
Prior art date
Application number
BR112016012237-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016012237A2 (https=
Inventor
Bryan M. Lewis
Yongbo Hu
Huiming Zhang
Hiroyuki Chiba
Yuki Komatsu
Original Assignee
Eisai R&D Management Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd filed Critical Eisai R&D Management Co., Ltd
Publication of BR112016012237A2 publication Critical patent/BR112016012237A2/pt
Publication of BR112016012237B1 publication Critical patent/BR112016012237B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112016012237-2A 2013-12-06 2014-12-05 Métodos úteis na síntese de análogos de halicondrina b BR112016012237B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912714P 2013-12-06 2013-12-06
US61/912,714 2013-12-06
PCT/US2014/068834 WO2015085193A1 (en) 2013-12-06 2014-12-05 Methods useful in the synthesis of halichondrin b analogs

Publications (2)

Publication Number Publication Date
BR112016012237A2 BR112016012237A2 (https=) 2017-08-08
BR112016012237B1 true BR112016012237B1 (pt) 2023-02-07

Family

ID=53270478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016012237-2A BR112016012237B1 (pt) 2013-12-06 2014-12-05 Métodos úteis na síntese de análogos de halicondrina b

Country Status (13)

Country Link
US (4) US9303039B2 (https=)
EP (2) EP3077399B1 (https=)
JP (3) JP6443812B2 (https=)
CN (1) CN105916861B (https=)
BR (1) BR112016012237B1 (https=)
CA (1) CA2931788C (https=)
ES (1) ES2723355T3 (https=)
HU (1) HUE043088T2 (https=)
IL (4) IL245661A0 (https=)
MX (3) MX384292B (https=)
RU (1) RU2676486C1 (https=)
SG (2) SG11201604545XA (https=)
WO (1) WO2015085193A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP3689881B1 (en) * 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (es) * 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
EP3413887B1 (en) * 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
ES2931533T3 (es) * 2017-04-05 2022-12-30 Harvard College Compuesto macrocíclico y usos del mismo
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2018217894A1 (en) * 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
CN111566113B (zh) 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
SG11202005548WA (en) 2018-01-03 2020-07-29 Eisai R&D Man Co Ltd Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
JP2021532102A (ja) * 2018-07-20 2021-11-25 ドクター レディズ ラボラトリーズ リミテッド エリブリンおよびその中間体の調製のための精製プロセス
EP3864011A4 (en) * 2018-10-09 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for preparation of eribulin and intermediates thereof
US12522611B2 (en) * 2018-11-28 2026-01-13 Natco Pharma Limited Process for the preparation of high pure Eribulin and its Mesylate salt
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
WO2022101931A1 (en) * 2020-11-10 2022-05-19 Natco Pharma Limited Process for the preparation of eribulin and its intermediates
CN113354659B (zh) * 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
CN114380840B (zh) * 2022-01-27 2024-01-26 江苏慧聚药业股份有限公司 艾日布林的合成
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (https=) 1992-09-09 1995-09-01 Hoechst Ag
WO1998009942A1 (en) 1996-09-06 1998-03-12 Eli Lilly And Company Catalytic selective sulfonylation process
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6214865B1 (en) 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SEARCH FOR TUBULINISOTYPES IN CANCER THERAPY USING HALICHONDRIN B ANALOG
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
RU2010118063A (ru) 2007-11-16 2011-12-27 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения
CN105801599A (zh) 2008-04-04 2016-07-27 卫材R&D管理有限公司 软海绵素b类似物
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
WO2011094339A1 (en) 2010-01-26 2011-08-04 Eisai R&D Management Co., Ltd. Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
WO2013142999A1 (en) 2012-03-30 2013-10-03 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
EP3689881B1 (en) 2013-11-04 2022-01-12 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b
MX384292B (es) * 2013-12-06 2025-03-14 Eisai R&D Man Co Ltd Metodos utiles en la sintesis de analogos de halicondrina b.
KR102743950B1 (ko) 2015-05-07 2024-12-18 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 마크롤라이드의 합성에 유용한 마크로고리화 반응 및 중간체 및 기타 단편
EP3413887B1 (en) 2016-02-12 2021-04-07 Eisai R&D Management Co., Ltd. Intermediates in the synthesis of eribulin and related methods of synthesis
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof

Also Published As

Publication number Publication date
IL273736B (en) 2021-03-25
JP6905041B2 (ja) 2021-07-21
EP3505520A1 (en) 2019-07-03
US20170298078A1 (en) 2017-10-19
EP3077399A4 (en) 2017-05-10
IL273736A (en) 2020-05-31
US10030032B2 (en) 2018-07-24
SG11201604545XA (en) 2016-07-28
BR112016012237A2 (https=) 2017-08-08
MX376869B (es) 2025-03-07
CA2931788A1 (en) 2015-06-11
ES2723355T3 (es) 2019-08-26
EP3077399B1 (en) 2019-02-20
WO2015085193A1 (en) 2015-06-11
JP2016540752A (ja) 2016-12-28
CN105916861A (zh) 2016-08-31
US9695188B2 (en) 2017-07-04
US20160176895A1 (en) 2016-06-23
CN105916861B (zh) 2018-12-14
IL281275A (en) 2021-04-29
US20150158881A1 (en) 2015-06-11
IL281275B (en) 2021-12-01
MX2020004855A (es) 2021-07-08
JP2019031530A (ja) 2019-02-28
CA2931788C (en) 2022-05-24
IL265640A (en) 2019-05-30
RU2676486C1 (ru) 2018-12-29
MX2016006891A (es) 2017-06-12
JP2020059739A (ja) 2020-04-16
MX370611B (es) 2019-12-18
EP3077399A1 (en) 2016-10-12
US9303039B2 (en) 2016-04-05
IL245661A0 (en) 2016-06-30
US10450324B2 (en) 2019-10-22
IL265640B (en) 2020-04-30
JP6634135B2 (ja) 2020-01-22
MX2019011926A (es) 2019-11-18
MX384292B (es) 2025-03-14
SG10201805024YA (en) 2018-07-30
US20190010166A1 (en) 2019-01-10
JP6443812B2 (ja) 2018-12-26
HUE043088T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
JP6634135B2 (ja) ハリコンドリンb類縁体の合成に有用な方法
RU2579511C2 (ru) Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
EP2640730B1 (en) Processes for preparation of everolimus and intermediates thereof
JP6425727B2 (ja) 大環状hcv ns3阻害トリペプチド
RU2603261C2 (ru) Региоселективное ацилирование рапамицина в положении с-42
ES2752552T3 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
JP2022046542A (ja) 細胞毒性ベンゾジアゼピン誘導体の調製方法
CN107735398A (zh) 用于合成雷帕霉素衍生物的方法
CN101307084A (zh) 地西他滨(Decitabine)的合成工艺
JP2007506792A (ja) 9,10−α,α−OH−タキサンアナログおよびその生成のための方法
CN109694379B (zh) 用于制备艾日布林的中间体及其制备方法
ES2939049T3 (es) Proceso para preparar derivados de purina
ES2991258T3 (es) Procedimientos y productos intermedios para producir compuestos de diazaespiro-lactama
CN109415383A (zh) 制备艾日布林的方法及其中间体
JP6528251B2 (ja) (s)−1−((2r,3r,4s,5s)−5−アリル−3−メトキシ−4−(トシルメチル)テトラヒドロフラン−2−イル)−3−アミノプロパン−2−オールの結晶性誘導体
ES2295663T3 (es) Gamma-lactona cristalina de acido 17beta-hidroxi-7alfa-(5'-metil-2' -furil)-pregna-4,9(11)-dien-3-ona-21-carboxilico.
CN106132972B (zh) 用于治疗hcv感染的氨基磷酸酯
JP2025539267A (ja) ヌクレオシド誘導体nuc-3373の合成
TW202540077A (zh) 具有抗癌活性之mdm2-p53交互作用的異吲哚啉酮抑制劑的中間體的製造方法

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 491/22

Ipc: C07D 491/22 (2006.01), A61P 35/00 (2006.01)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2014, OBSERVADAS AS CONDICOES LEGAIS